CEO DIALOGUE #35 - Lars Fruergaard Jørgensen, Novo Nordisk

Lars Fruergaard Jørgensen, CEO of Novo Nordisk, which makes game changing obesity drugs Ozempic and Wegovy, explains to Jean-François Manzoni how its culture and long-view underpin its recent turnaround. 0:00 🇩🇰 Introduction to Lars Fruergaard Jørgensen and Novo Nordisk 2:17 🧫 GLP-1 Therapies and Turbocharged Growth 7:15 🇺🇸 Corporate Governance and Entering the U.S. Market 11:51 🧠 The Novo Nordisk Way: A Culture of Innovation 18:35 💊 The Obesity Market: Weight-loss Drugs and Historic Safety Issues 21:18 📈 Novo Nordisk's Expansion Project 31:43 🫀 Public Price Pressures in Healthcare 38:34 🥇 Earning the Right to Lead Novo Nordisk 42:21 👂 Listening and the Importance of Gut Feelings 47:10 👪 People, Patients, Products ➡️ Subscribe to IMD: https://www.imd.org/ About our CEO Dialogue Series: Explore in-depth discussions between top executives and IMD President Jean-François Manzoni to learn how to develop your leadership skills and explore trending topics. Connect with IMD: Find out about this series: https://www.imd.org/ibyimd/ Follow IMD on Instagram:   / imdbusinessschool   Follow IMD on LinkedIn:   / imd-business-school   Follow IMD on Facebook:   / imdbschool   Follow IMD on BlueSky: https://bsky.app/profile/imdbusinesss... #imdimpact